AI-powered apps and bots enter healthcare, raising concerns among doctors

AI-powered apps and bots enter healthcare, raising concerns among doctors


Artificial intelligence is shaking up
industries from software and law to entertainment and education.
And as physicians like Dr. Cem Aksoy are learning, it’s posing
special challenges in medicine as patients tap AI for advice.

Aksoy, a medical ​resident at a hospital in Ankara, Turkey,
says an 18-year-old patient and his family recently panicked
after the young man was diagnosed with a cancerous ‌tumor on his
left leg. They turned to OpenAI’s ChatGPT. The bot said he might
survive only five years.

It was wrong: A plastic surgeon successfully removed the
tumor ​in July. “He was essentially cured after the operation,”
Aksoy said.

But a few weeks later, the patient called Aksoy on the verge
of tears. “He said, ‘I started coughing recently, and ChatGPT
told me it could possibly be metastasis to my lungs,’” meaning
the cancer had spread, the doctor recalled. The patient said he
needed to write a will. It turned out his lungs were fine. He
was coughing because he’d recently started smoking.

“When someone is distressed and unguided,” Aksoy said, an AI
chatbot “just drags them into this forest of knowledge without
coherent context.”

A spokesperson for OpenAI said its newest models have
significantly improved how they handle health questions. ChatGPT
isn’t intended as a substitute for a medical professional’s
guidance, the company said.

The young Turkish patient’s encounter with AI-dispensed
medical wisdom comes as many patients around the world are
turning to the technology for advice. In addition to the big
ask-me-anything chatbots, consumers are turning to a slew of
new, AI-powered consumer medical apps.

‘BECOME ​YOUR OWN DOCTOR’

A growing number of mobile apps available on the Apple and
Google app stores claim to use AI to assist patients with their
medical complaints – even ⁠though they’re not supposed to offer
diagnoses.

Under U.S. Food and Drug Administration guidelines, AI-based
medical apps don’t require approval if they “are intended
generally for patient education, and are not intended for use in
the diagnosis of disease or other conditions.” Many apps have
disclaimers that they aren’t a diagnostic tool and shouldn’t be
used as a substitute for a physician. Some developers seem to be
stretching the limits.

An app called “Eureka Health: AI Doctor” touted itself as
“Your all-in-one personal health companion.” ​It stated on
Apple’s App Store that it was “FOR INFORMATIONAL PURPOSES ONLY”
and “does not diagnose ⁠or treat disease.”

But its developer, Sam Dot Co, also promoted the app on a
website, where it stated in big letters: “Become your own
doctor.”

“Ask, diagnose, treat,” the site stated. “Our AI doesn’t
just diagnose – it connects you to prescriptions, lab orders,
and real-world care.”

Apple said that after learning about Eureka Health from
Reuters, it removed it from its app store. Apple’s guidelines
for developers states that medical apps “must clearly disclose
data and methodology to support accuracy claims.”

App developer Sam Dot didn’t respond to a request for
comment. But the website changed after Reuters inquired ‌about
it. The site no longer mentions the app.

In some cases, apps have given inaccurate and potentially
dangerous advice.

“AI Dermatologist: Skin Scanner” says on its website that it
has ‌more than 940,000 users and “has the same accuracy as a
professional dermatologist.” Users can upload photos of moles
and other skin conditions, and AI provides an “instant” risk
assessment. “AI Dermatologist can save your life,” the site
claims.

Its Lithuania-based developer, Acina, says the app uses “a
proprietary neural network” that looks for patterns to make
predictions. Acina ‍says it was trained on dermatological images
to recognize specific skin conditions.

DERMATOLOGY APP CLAIMS ‘97% ACCURACY’

The app claims “over 97% accuracy.” But it has drawn
hundreds of one-star reviews on app stores, and many users
complain it’s inaccurate.

Daniel Thiberge, a tech-support analyst in New Jersey, told
Reuters that he bought the app to interpret seven pictures he
snapped of a small growth on his arm. Six results showed there
was a “75%-95%” ‍risk it was cancerous, he said. He then went to
a dermatologist. The doctor told him the growth didn’t look
problematic in any way, and it wasn’t worth doing a biopsy.

“If it’s completely, wildly off, what is the purpose of the
app?” Thiberge asked. At best it’s useless, he said. “At worst,
it’s dangerous, because you may not go see a dermatologist.”

In another review on the Apple App Store, a user wrote that
to test the app, she uploaded photos showing she had melanoma, a
serious form of skin cancer, that had been diagnosed and
surgically removed. But the app reported that the condition was
“benign,” wrote the user. She told Reuters that she fears “some
people will trust it and delay doctor visits.”

Reuters didn’t independently confirm the app users’
experiences. Acina said it couldn’t verify them. It told Reuters
that AI Dermatologist’s “purpose is not to provide a medical
diagnosis, but to offer a preliminary analysis using AI
technology to encourage users to consult a professional.”

“Our AI models are built upon dermatological literature and
carefully curated datasets that were selected and validated by
board-certified dermatologists,” it said, adding that “false
positives can happen with any AI system.”

A DOCTOR WORRIES ABOUT APPS’ ACCURACY

The company said its AI has ⁠received many positive online
reviews, including “where users thank us because the app
prompted them to check a mole or lesion early – in some cases
leading to timely medical attention.”

Apple said it removed the app from its App Store after
learning about it from Reuters, in part because of the numerous
customer complaints.

Google also removed ​AI Dermatologist from its Google Play
store after Reuters called attention to the app. “Google Play
prohibits apps from offering misleading or harmful health
functionality and requires regulatory proof or a disclaimer for
apps offering medical functionality,” ⁠the spokesman said.

But the app is back on the market. Google recently
reinstated it after Acina revised it. Google said suspended apps
can return if they’re updated with a “compliant version.”

Acina said it “clarified more explicitly that the app is not
a medical device,” doesn’t provide diagnoses, and that users
should consult healthcare professionals.

Apple also briefly reinstated it, but then removed it again
last week. According to Acina, Apple told it that “upon
re-evaluation,” it determined this: “The app provides medical
related data, health related measurements, diagnoses or
treatment advice without the appropriate regulatory clearance.”
Acina said it is appealing the removal.

Dr. Rachel Draelos, a physician, computer scientist and
consultant in AI healthcare, says AI-powered medical apps are
worrisome, particularly in dermatology. “I’m very concerned by
it ⁠because properly identifying skin things is really hard,” she
told Reuters. There are thousands of skin conditions, and
“there’s no way that all of these apps actually have a dataset
that covers all these things.”

Published on February 9, 2026



Source link

MFIs push for real-time credit data, regulator hesitant to approve

MFIs push for real-time credit data, regulator hesitant to approve


The Central bank, however, is unlikely to approve this request considering the significant operational changes that lenders and credit bureaus will have to make in their existing technology infrastructure to adopt the practise.
| Photo Credit:
Andrii Yalanskyi

Considering the unsecured nature of small-ticket loans, micro-finance institutions (MFIs) in their latest meeting with the banking regulator requested the Reserve Bank of India (RBI) to mandate daily credit bureau updates from all lenders on the microfinance portfolio. The Central bank, however, is unlikely to approve this request considering the significant operational changes that lenders and credit bureaus will have to make in their existing technology infrastructure to adopt the practise.

“Since January last year, the RBI requires all lenders to update credit bureau records every 15 days. But our set of borrowers could apply with many institutions and take small-ticket and short tenure loans in that period. It is important that we track their credit history on a real-time basis, else they may avail an additional loan/s and we realise it only after 15 days. The recent over-leveraging of borrowers issue in the MFI sector partly happened because of this lag in data collection,” said a senior official of a MFI requesting annonymity.

However, this request will lead to massive data pile-up with the credit bureaus, and will be hard to implement by different categories of lenders, especially lenders who have small sized balance sheet with limited technology infrastructure in place, said people aware of the regulator’s thinking.

Further, MFIs have also requested the RBI to allow bio-metric enabled Aadhar card as a borrower authentication document. While the central bank is amenable to this request, it has to be approved by the Central government or by the apex court as the Supreme Court in 2017 ruled that lenders cannot mandate Aadhaar for authentication of borrowers.

“Post the 2017 court verdict, many MFIs are relying on voter IDs and PAN cards as authentication documents. These documents are not bio-metric enabled and can be manipulated. It is also critical that the KYC ID and the ID used in the credit bureau is the same for correct data” a source said.

Published on February 9, 2026



Source link

RBI approves Vijay Anandh as new MD and CEO of City Union Bank w.e.f May 1

RBI approves Vijay Anandh as new MD and CEO of City Union Bank w.e.f May 1


R Vijay Anandh, new MD & CEO, City Union Bank
| Photo Credit:
Bijoy Ghosh

City Union Bank on Monday said that Reserve Bank of India (RBI) had approved the appointment of R Vijay Anandh, currently the Executive Director (ED) at the private bank, as the next Managing Director & CEO.

RBI vide its letter dated February 9, 2026, has conveyed its approval for the appointment of R Vijay Anandh as MD & CEO of the bank for a period of 3 years w.e.f May 1, 2026, along with remuneration, City Union Bank said in an exchange filing. The appointment shall be subject to approval of shareholders of the bank.

RBI’s approval letter to CUB, as seen by businessline, mentions the remuneration to be a fixed pay of ₹2.50 crore per annum including perquisites.

Anandh holds over 28 years of experience in banking, risk management, Portfolio Analysis, Credit Appraisals, and other retail banking segments. Prior to his appointment in City Union Bank, he served as the Business and Collections Head for Retail Asset products at RBL Bank, working closely with the ED & the MD there. He was first appointed as Executive President at CUB in 2023, and was designated as ED in 2024.

N Kamakodi has been serving as MD & CEO of CUB since May 2011, and his term ends on April 30, 2026.

Published on February 9, 2026



Source link

BSE Q3 profit jumps 174% to ₹602 crore on strong trading, higher income

BSE Q3 profit jumps 174% to ₹602 crore on strong trading, higher income


FILE PHOTO: A man walks out of the Bombay Stock Exchange building in Mumbai
| Photo Credit:
HEMANSHI KAMANI

India’s oldest stock exchange, BSE, reported a sharp 174 per cent year-on-year jump in consolidated net profit for the December quarter, aided by robust trading activity and higher operating income.

The exchange posted a net profit of ₹602 crore in Q3FY26, compared with ₹220 crore in the same period last year. The profit after tax is attributable to shareholders of the holding company.

Revenue from operations during the quarter rose 62 per cent year-on-year to ₹1,244 crore, from ₹768 crore in the corresponding quarter of the previous financial year.

On a sequential basis, BSE reported steady growth. Net profit increased 8 per cent from ₹558 crore in Q2FY26, while revenue rose 16 per cent from ₹1,068 crore recorded in the July–September quarter of FY26.

Published on February 9, 2026



Source link

Micro, small enterprises with good track record can get collateral-free loans up to ₹25 lakh: RBI

Micro, small enterprises with good track record can get collateral-free loans up to ₹25 lakh: RBI


Banks can accept gold and silver as collateral if pledged voluntarily by MSE (micro and small enterprise) borrowers for loans sanctioned by them up to the collateral free limit of ₹20 lakh, per RBI’s amendment directions on lending to micro, small & medium enterprises (MSME) sector.

Further, banks may, on the basis of good track record and financial position of the MSE units, increase the limit for loans up to ₹25 lakh as per their internal policy.

With a view to facilitating improved access to formal credit, support entrepreneurial activity and strengthen last mile credit delivery for MSEs with limited collateral, RBI last Friday said the limit of collateral free loans to MSEs will be doubled from ₹10 lakh to ₹20 lakh.

Banks are mandated not to accept collateral security in the case of loans up to ₹20 lakh extended to units in the MSE sector. They are also required to extend collateral-free loans up to ₹20 lakh to all units financed under the Prime Minister Employment Generation Programme (PMEGP) administered by KVIC (Khadi and Village Industries Commission).

Further, banks may avail of the benefit of credit guarantee scheme cover, where applicable.

The central bank said the amendments have been carried out to (i) enhance the extant collateral-free loan limit for MSEs to ₹20 lakh, and (ii) align with certain regulatory changes.

The objective is to strengthen last mile credit delivery for MSEs with limited assets to provide as collateral. RBI said the amended directions will come into effect from April 1, 2026.

Published on February 9, 2026



Source link

RBI Guv flags the need to remain vigilant against KYC-related frauds and misuse of accounts

RBI Guv flags the need to remain vigilant against KYC-related frauds and misuse of accounts


Sanjay Malhotra, Governor of the Reserve Bank of India
| Photo Credit:
DHIRAJ SINGH

Reserve Bank of India Governor Sanjay Malhotra on Monday flagged the need to remain vigilant against KYC (know-your-customer)-related frauds and misuse of accounts.

Malhotra addressed a gathering of the top management and Regional Heads of the Reserve Bank, NABARD and heads of select commercial banks at the launch of the 11th edition of Financial Literacy Week (FLW), whose theme is ‘KYC – Your First Step to Safe Banking’.

He urged banks to utilise FLW to spread awareness among their customers on the importance and ease of KYC and re-KYC, the role of the Central KYC Records Registry (CKYCR) in simplifying customer onboarding.

The Governor underscored the significance of KYC for safe, secure, and inclusive banking. The FLW 2026 will be observed between February 9 and 13, 2026, across the country.

Published on February 9, 2026



Source link

YouTube
Instagram
WhatsApp